BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company would be presenting at
the 27th Annual International Atrial Fibrillation Symposium on
January 13-15, 2022.
Clinical observations collected with BioSig’s PURE EP™ System
will be presented by DJ Lakkireddy, M.D., Kansas City Heart Rhythm
Institute at HCA Midwest Health during Spotlight Session: Complex
AF Case Study Utilizing a New Standard in Signal Processing on
January 13, 2022, from 8:30-9:30 AM ET.
“Dr. Lakkireddy is highly regarded for his passionate commitment
to those suffering from complex arrhythmias and for his leadership
in the field of electrophysiology, and we are thrilled to have him
represent our technology at this benchmark industry event. We would
like to thank the course directors, Drs. Ruskin, Mansour, Reddy,
Keane, Jais, and the entire faculty for bringing the
electrophysiology community together during this important industry
event. We look forward to reconnecting with our physician partners
and our peers as we gear up for an impactful clinical and
commercial year,” commented Kenneth L. Londoner, Chairman, and CEO
of BioSig Technologies, Inc.
During the event, BioSig will be exhibiting at booth 403. The
Company’s executive, commercial and clinical teams will host
demonstrations of the PURE EP™ System and some of its platform
technology's latest software and algorithmic features for
arrhythmia care.
The conference will also be broadcast live. To register
for the event and stream the live presentation, please follow this
link:
https://register.rcsreg.com/r2/afs2022/ga/top.html
To date, more than 73 physicians have completed over 1800
patient cases with the PURE EP™ System. The Company is in a
focused commercial launch of the PURE EP™ System in the Northeast,
Texas, and Florida.
Clinical data acquired by the PURE EP™ System in a multi-center
study at Texas Cardiac Arrhythmia Institute at St. David’s Medical
Center, Mayo Clinic Jacksonville, and Massachusetts General
Hospital was recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93%
consensus across the blinded reviewers with a 75% overall
improvement in intracardiac signal quality and confidence in
interpreting PURE EP™ signals over conventional sources.
One in 18 Americans suffers from a cardiac arrhythmia. Atrial
fibrillation is the most common arrhythmia type, affecting over 33
million people worldwide, including over 6 million in the U.S. The
number of people suffering from atrial fibrillation is expected to
reach 8-12 million by 20501. According to the Centers for
Disease Control and Prevention (CDC), atrial fibrillation causes
more than 750,000 hospitalizations in the U.S. each year, resulting
in approximately $6 billion in healthcare spending annually2.
About 277h Annual International AF Symposium
This intensive, highly focused three-day symposium brings together
the world’s leading medical scientists to share in a highly
interactive environment the most recent advances in the field of
atrial fibrillation. The primary objective of the meeting is to
provide attendees with a thorough and practical course on the
current state of the art in the field of atrial fibrillation in a
scholarly and collegial atmosphere, as well as an opportunity to
network with colleagues and faculty between sessions. More
information about the event on www.afsymposium.com.
About BioSig Technologies BioSig Technologies is a
medical technology company commercializing a proprietary biomedical
signal processing platform designed to improve signal fidelity and
uncover the full range of ECG and intra-cardiac signals
(www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording, and storing
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Top 10 Things You should Know About Heart Rhythm; Scripps
Health.
2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical
Economics Journal, February 25, 2019, Volume 96, Issue 4
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880,
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024